Endocrine Abstracts

Introduction: Bariatric surgery (BS) is an effective method to weight loss, however, some patients experience persistence of physical inactivity or even weight gain over the years. Furthermore, It is not clear if some surgical techniques, mainly those with disabsortive components, could be involved in the low physical performance through interfering with nutritional status This study aimed to evaluate physical function (PF), quality of life (QOL) and energy expenditure (EE) du...

Background: Acromegaly is a severe systemic condition characterized by elevated circulating levels of growth hormone (GH) and insulin-like growth factor I (IGF-I) and increased mortality and morbidity. The role of GH and IGF-I in mammary hyperplasia is well established and GH/IGF-I elevation has been hypothesized to favor neoplastic development. We recently demonstrated that premenopausal females with active acromegaly may display an increased mammographic breast density (MBD)...

Fibroblast growth factor 21 (FGF21) is an emerging regulator of energy homeostasis and a novel target for the development of therapies to treat diabetes, cardiovascular disease, and obesity. FGF21 was discovered in an in vitro high throughput screen. It was later shown to have impressive metabolic pharmacology including glucose, lipid, and body weight lowering effects in a variety of animal models, including non-human primates. When tested clinically an FGF21-based an...

Kisspeptin is a neuropeptide secreted in anteroventral-periventricular and arcuate hypothalamic nuclei involved pubertal onset and in other functions of adult life. Kisspeptin levels are sex dependent, so they are higher in prepubertal girls and in adult women compared to age-matched male. This sex-related pattern has been reported in adult obesity, but few data are reported in childhood obesity. In order to evaluate correlations between metabolic status and kisspeptin, we stu...

Introduction: Agonist receptor-GLP1 (AR-GLP1) had demonstrated its utility in obese patients with diabetes type 2. Since August 2013 we have available in Spain a new AR-GLP1 with prandial action in a single daily dose, lixisenatide. There are different clinical trials that support its efficacy and security but the dates from real clinical practice are scarce.Aim: To analyse the efficacy and security in real clinical practice for the treatment of diabetic...

Introduction: Thyroid gland involvement by Langerhans Cell Histiocytosis (LCH) is a very rare condition. It occurs by thyroid infiltration that may result in hypothyroidism. LCH may be also related to neoplastic processes such as leukemias or lymphomas. However, the association with papillary thyroid carcinoma (PTC) is exceptional. We introduce a case and review the reported cases of this association.Case report: We describe a 33 year old patient diagnos...

Introduction: The management of craniopharyngioma (CR) remains a challenge. The introduction of endoscopic technique in the surgical approach to the sellar/suprasellar region would have profound implications for treatment. The aim of the study was to analyze results, advantages and limits of endoscopic endonasal approach (EEA).Design/methods: From 1998 to 2012, 95 patients underwent surgery for CR. Trancranial approach was chosen for 33 patients (35%) on...

Introduction: The ideal strategy and the role of the different therapeutic options in acromegaly remain unclear. This research focuses on observing treatment options, and the respective level of disease control in acromegaly.Methods: A retrospective chart audit was conducted in US, France, Italy, and Brazil (September 2012). 97 endocrinologists completed structured case report forms for the 4 most recently-seen patients (two with somatostatin analogues (...

Circulating estrogens decrease after the menopause from 60–400 to 5–30 pg/ml in postmenopausal women and in men are below 30 pg/ml. These low physiological concentrations present an analytical challenge. Analysis of steroids by tandem mass spectrometry is attractive due to its high specificity compared with immunoassays. However, estrogens do not ionise efficiently and therefore chemical modifications are necessary to achieve the sensitivity required.<p class="ab...

Raloxifene is a selective estrogen receptor modulator which has shown to decrease bone resorption, increase bone density and reduce vertebral fracture rate in women with postmenopausal osteoporosis. Recent studies have shown a decrease on breast cancer incidence after raloxifene treatment. Although the mechanism is not clear, its mixed agonist and antagonist properties in different tissues could partially explain this effect.Objective: To evaluate the ef...